脈絡膜新生血管治療薬の世界市場2016-2020

◆英語タイトル:Global Choroidal Neovascularization Market 2016-2020
◆商品コード:IRTNTR8546
◆発行会社(リサーチ会社):Technavio
◆発行日:2016年2月24日
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、脈絡膜新生血管治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、脈絡膜新生血管治療薬の世界市場規模及び予測、地域別分析/市場規模、購買基準、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況などの情報をお届けいたします。
【レポートの概要】

About Choroidal Neovascularization

Choroidal neovascularization is the formation of new blood vessels in the choroid layer of the eye. These vessels grow through the Bruch membrane into the subretinal space, blocking the proper functioning of retina and leading to vision loss. The condition is often associated with myopia, malignant myopic degeneration, or age-related macular degeneration (AMD).

Technavio’s analysts forecast the global choroidal neovascularization market to grow at a CAGR of 6.64% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global choroidal neovascularization market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment and prevention of choroidal neovascularization.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Choroidal Neovascularization Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Bayer HealthCare
• Novartis
• Regeneron Pharmaceuticals
• F. Hoffmann-La Roche

[Other prominent vendors]
• Alcon
• Allergan
• Avalanche
• Bausch and Lomb
• Gilead Sciences
• Iconic Therapeutics
• Lpath
• Neurotech Pharmaceuticals
• Ohr Pharmaceutical
• Opthea
• Ophthotech
• PanOptica
• Pfizer
• Promedior
• QLT
• Quark
• Resolvyx Pharmaceuticals
• RXi Pharmaceuticals
• Sagent Pharmaceuticals
• Santen
• Sanwa Kagaku Kenkyusho

[Market driver]
• Growing older population
• For a full, detailed list, view our report

[Market challenge]
• High cost of treatment
• For a full, detailed list, view our report

[Market trend]
• Strategic alliances and M&A
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights
• Key buying criteria

PART 05: Disease overview
• Introduction
• Pathophysiology
• Symptoms
• Management
• Epidemiology

PART 06: Product portfolio of approved therapies

PART 07: Pipeline analysis
• OHR-102
• RTH258
• Fovista
• RG7716
• PF-04523655
• NT-503
• LFG316
• REGN2176-3
• Zimura
• LHA510
• DE-120

PART 08: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 09: Market segmentation by ROA
• IV
• Intravitreal

PART 10: Geographical segmentation
• Global choroidal neovascularization market by geographical segmentation 2015-2020
• Choroidal neovascularization market in Americas
• Choroidal neovascularization market in EMEA
• Choroidal neovascularization market in APAC

PART 11: Market drivers
• Growing older population
• Increased prevalence of chronic diseases
• High patient and physician satisfaction
• Increase in diagnosis rate

PART 12: Impact of drivers

PART 13: Market challenges
• High cost of treatment
• Limited public awareness
• Side effects associated with treatment options
• Availability of alternative therapies

PART 14: Impact of drivers and challenges

PART 15: Market trends
• Strategic alliances and M&A
• Increased initiatives and programs
• Use of combination therapies
• Increase in R&D

PART 16: Vendor landscape
• Competitive scenario
• Market analysis 2015
• F. Hoffmann-La Roche
• Novartis
• Regeneron Pharmaceuticals
• Bayer HealthCare
• Other prominent vendors

PART 17: Appendix
• List of abbreviations

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings 7
Exhibit 02: Key buying criteria for choroidal neovascularization drugs
Exhibit 03: Types of choroidal neovascularization
Exhibit 04: Symptoms of choroidal neovascularization
Exhibit 05: Treatment options for choroidal neovascularization
Exhibit 06: Pipeline portfolio: Global choroidal neovascularization therapeutics
Exhibit 07: Global choroidal neovascularization market 2015-2020 ($ billions)
Exhibit 08: Five forces analysis
Exhibit 09: Segmentation of global choroidal neovascularization market by ROA 2015
Exhibit 10: Market segmentation by geography 2015
Exhibit 11: Choroid neovascularization market revenue by geography 2015-2020 ($ billions)
Exhibit 12: Choroidal neovascularization market in Americas 2015-2020 ($ billions)
Exhibit 13: Choroidal neovascularization market in EMEA 2015-2020 ($ billions)
Exhibit 14: Choroidal neovascularization market in APAC 2015-2020 ($ millions)
Exhibit 15: Global choroidal neovascularization market: YoY growth and revenue based on geography 2015-2020
Exhibit 16: Impact of drivers
Exhibit 17: Impact of drivers and challenges
Exhibit 18: Vendor ranking of global choroidal neovascularization market 2015
Exhibit 19: Roche: YoY growth and revenue of Avastin 2011-2014 ($ billions)
Exhibit 20: Roche: YoY growth and revenue of Lucentis 2011-2014 ($ billions)
Exhibit 21: Roche: Key takeaways
Exhibit 22: Novartis’ specialty ophthalmic segmentation by revenue 2014
Exhibit 23: Novartis: YoY revenue and growth rate of Lucentis (excluding the US) 2012-2014 ($ millions)
Exhibit 24: Novartis: Key takeaways
Exhibit 25: Regeneron: YoY revenue and growth rate of EYLEA (in the US) 2012-2014 ($ billions)
Exhibit 26: Regeneron Pharmaceuticals: Key takeaways
Exhibit 27: Bayer HealthCare: YoY revenue and growth rate of EYLEA 2012-2014 ($ millions)
Exhibit 28: Bayer HealthCare: Key takeaways



【掲載企業】

Bayer HealthCare, Novartis, Regeneron Pharmaceuticals, F. Hoffmann-La Roche, Alcon, Allergan, Avalanche, Bausch and Lomb, Gilead Sciences, Iconic Therapeutics, Lpath, Neurotech Pharmaceuticals, Ohr Pharmaceutical, Opthea, Ophthotech, PanOptica, Pfizer, Promedior, QLT, Quark, Resolvyx Pharmaceuticals, RXi Pharmaceuticals, Sagent Pharmaceuticals, Santen, Sanwa Kagaku Kenkyusho.

【レポートのキーワード】

脈絡膜新生血管、治療薬、医薬品

【リサーチ方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[脈絡膜新生血管治療薬の世界市場2016-2020]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆